RE: Absolutley4 Dec 2020 13:37
Yep,
40 to 46p is a decent buy price IMO. 46p being the recent placing price for institution's. Might hit a rough patch along the way but the volume is quite decent and that will need to continue. My target before approval is 78p which is the year high. I will have top sliced by then.
After approval? God knows but a novel non invasive cancer diagnostic that is, proven peer reviewed with FDA approved. Don't forget we are not waiting for phase 3 or 4 clinical approval it would be commercialised immediately.
Think Andrew Newland (yes he does look like Beaker out of the muppets) did a webinar with LSE or proactive which covers everything.
My only caveat is that is that much like DNL, it may be a bit shaky but will get there. Looks like Jupiter may have stopped selling or sold out, waiting for clarification, but again volume seems to be negating that.
Anyway yes, please DYOR.